Melanoma & Skin Cancer

Hussein A. Tawbi, MD, PhD, associate professor of medicine, The University of Texas MD Anderson Cancer Center, discusses evolving treatment for patients with melanoma.

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the inclusion of patients with brain metastases on melanoma clinical trials.

In an analysis of patient-reported outcomes of the JAVELIN Merkel 200 trial of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and patient-reported outcome endpoints.

An ongoing phase II study evaluating the PD-1 inhibitor cemiplimab in patients with basal cell carcinoma may prove efficacious based on its activity in other advanced malignancies.

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immuntep Ltd, discusses a novel immunotherapy combination in melanoma.

The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma.

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the promise of checkpoint inhibition in the treatment of melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses duration of checkpoint inhibitor therapy in patients with melanoma.

In the 44 years since John M. Kirkwood, MD began his career, he has seen melanoma become a growing field of research.

The treatment armamentarium for adjuvant melanoma has expanded rapidly, which has left the treatment challenge of selecting between immunotherapy and targeted therapy without any head-to-head comparative data.

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how to choose between combination therapies in the treatment of patients with melanoma.

Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses BRAF inhibitors for the treatment of patients with melanoma.

Hassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.